APA (7th ed.) Citation

Wistinghausen, B., Toner, K., Barkauskas, D. A., Jerkins, L. P., Kinoshita, H., Chansky, P., . . . Bollard, C. M. (2024). Durable immunity to EBV after rituximab and third-party LMP-specific T cells: A Children’s Oncology Group study. Blood advances, 8(5), 1116-1127. https://doi.org/10.1182/bloodadvances.2023010832

Chicago Style (17th ed.) Citation

Wistinghausen, Birte, et al. "Durable Immunity to EBV After Rituximab and Third-party LMP-specific T Cells: A Children’s Oncology Group Study." Blood Advances 8, no. 5 (2024): 1116-1127. https://doi.org/10.1182/bloodadvances.2023010832.

MLA (9th ed.) Citation

Wistinghausen, Birte, et al. "Durable Immunity to EBV After Rituximab and Third-party LMP-specific T Cells: A Children’s Oncology Group Study." Blood Advances, vol. 8, no. 5, 2024, pp. 1116-1127, https://doi.org/10.1182/bloodadvances.2023010832.